FDA approves new schizophrenia drug

Sept. 26 (UPI) -- The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday.

The drug, generically called Cobenfy, is the first oral medication to treat the disease that targets what are known as the brain's cholinergic receptors instead of dopamine receptors, which have been the traditional focus of treatment.

Advertisement